SetPoint Medical

SetPoint Medical is a private, commercial-stage biotech company that has successfully developed and gained FDA approval for the first device-based neuroimmune modulation therapy for rheumatoid arthritis. The company's core technology, the SetPoint System, represents a paradigm shift in autoimmune disease treatment by leveraging bioelectronic medicine to modulate the inflammatory response via the vagus nerve. With a landmark publication in Nature Medicine and recent CMS reimbursement approval, SetPoint is positioned to commercialize its RA therapy while advancing its platform into new indications, including multiple sclerosis. The company is backed by significant private financing, including a recent $140 million round, to support its launch and pipeline expansion.

Neuroimmune modulation via an implantable, wireless device that stimulates the cervical vagus nerve to activate the body's inflammatory reflex and restore immune balance.

SetPoint's direct competitors are other bioelectronic medicine companies targeting inflammatory diseases, though it holds a first-mover advantage with FDA approval in RA. Its broader competitive set includes all pharmaceutical companies marketing biologics and JAK inhibitors for RA and MS. SetPoint's key differentiation is its mechanism of action (device-based neuroimmune modulation), which offers a potentially favorable safety profile and a once-daily, minute-long treatment regimen.